文献速递物质与行为成瘾心境障碍

遗传模拟GLP1R与GIPR激动可减少暴饮及酒精相关表型:多祖先药物靶点孟德尔随机化研究

Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.
PubMed 文献 · Mol Psychiatry · 2025-09-10

该研究采用药物靶点孟德尔随机化,利用GIPR和GLP1R位点遗传变异模拟降低BMI和HbA1c的效应,评估其对问题性饮酒、暴饮、酒精滥用分类、肝脏健康及其他物质使用行为的影响。结果显示,遗传模拟的GIPR/GLP1R激动与暴饮减少、重度饮酒伴精神共病风险降低、NAFLD和ALT降低相关,而对烟草、大麻、阿片类使用障碍的估计一致为零。

要点

  • 遗传模拟GIPR/GLP1R激动降低BMI与暴饮减少相关,主要分析和复制数据均支持。
  • 遗传模拟GIPR/GLP1R激动降低HbA1c与重度饮酒伴精神共病风险降低相关,且与问题性饮酒减少方向一致。
  • GIPR和GLP1R两个靶点均对重度饮酒显示保护作用,支持双重激动剂在成瘾医学中的进一步临床探索。

核心结论

  • 遗传模拟的GIPR/GLP1R激动与暴饮减少、重度饮酒伴精神共病风险降低、NAFLD和ALT降低相关,支持GLP1R、GIPR及双重激动剂在成瘾医学中的进一步临床探索。

研究设计与样本

  • 药物靶点孟德尔随机化研究,利用GIPR和GLP1R位点遗传变异作为遗传代理,模拟降低BMI和HbA1c的效应。
  • 分析纳入多祖先队列,主要分析和复制数据均用于验证暴饮、重度饮酒伴精神共病、NAFLD和ALT等结局。

主要发现

  • 遗传模拟GIPR/GLP1R降低BMI与暴饮减少相关:主要数据β=-0.44(95%CI [-0.72, -0.15],P=2.42×10-3),复制数据β=-0.13([-0.22, -0.04],P=0.0058)。
  • 遗传模拟GIPR/GLP1R降低HbA1c与重度饮酒伴精神共病风险降低相关:OR=0.62([0.45, 0.85],P=0.0031),独立HbA1c数据复制OR=0.71([0.60, 0.84],P=5.22×10-5)。
  • GIPR和GLP1R单个位点分析均显示对重度饮酒的保护作用。
  • 遗传模拟GIPR/GLP1R降低BMI与脂肪食物喜好降低(β=-1.58,[-2.01, -1.14],P=1.62×10-12)和素食喜好增加(β=2.08,[1.17, 2.99],P=8.22×10-6)相关。
  • 遗传模拟GIPR/GLP1R降低HbA1c与NAFLD降低(β=-0.34,[-0.50, -0.18],P=2.74×10-5)和ALT降低(β=-0.26,[-0.38, -0.15],P=8.39×10-6)相关。

关键数值与推荐

  • 暴饮减少的主要分析β=-0.44(95%CI [-0.72, -0.15],P=2.42×10-3),复制数据β=-0.13([-0.22, -0.04],P=0.0058)。
  • 重度饮酒伴精神共病风险降低的OR=0.62([0.45, 0.85],P=0.0031),复制OR=0.71([0.60, 0.84],P=5.22×10-5)。
  • NAFLD降低β=-0.34([-0.50, -0.18],P=2.74×10-5),ALT降低β=-0.26([-0.38, -0.15],P=8.39×10-6)。

临床怎么用

  • 遗传证据支持GLP1R、GIPR及双重激动剂可能减少暴饮和重度饮酒伴精神共病风险,提示在成瘾医学中进一步临床探索的价值。
  • 对酒精使用障碍合并代谢异常或精神共病的患者,GLP1R/GIPR激动剂可能具有潜在获益,但需临床研究验证。

局限性

  • 研究为药物靶点孟德尔随机化,遗传代理模拟长期效应,不能直接等同于药物临床试验结果。
  • 其他物质使用障碍(烟草、大麻、阿片类)的估计一致为零,提示效应可能具有酒精特异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacological modulation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) through dual GIP/GLP-1 receptor agonists, commonly used for diabetes and obesity, shows promise in reducing alcohol consumption. We applied drug-target Mendelian randomization (MR) using genetic variation at these loci to assess their long-term effects on problematic alcohol use (PAU), binge drinking, alcohol misuse classifications, liver health, and other substance use behaviors. Genetic proxies for lowered BMI, modeling the appetite-suppressing and weight-reducing effects of variants in both the GIPR and GLP1R loci ("GIPR/GLP1R"), were linked with reduced binge drinking in the primary (β = -0.44, 95% CI [-0.72, -0.15], P = 2.42 × 10-3) and replication data (β = -0.13, [-0.22, -0.04], P = 0.0058). HbA1c lowering via GIPR/GLP1R variants was associated with reduced risk of heavy drinking with psychiatric comorbidities versus low-risk drinking (odds ratio [OR] = 0.62, [0.45, 0.85], P = 0.0031), with replication in independent HbA1c data (OR = 0.71, [0.60, 0.84], P = 5.22 × 10-5) and directional consistency with reduced PAU. Analysis of individual loci indicated that both GIPR and GLP1R were protective against heavy drinking, underscoring the importance of both targets. While estimates for other substance use disorders (tobacco, cannabis, opioid) were consistently null, food preference analyses revealed that BMI lowering via GIPR/GLP1R reduced fatty food liking (β = -1.58, [-2.01, -1.14], P = 1.62 × 10-12) and increased vegetarian food liking (β = 2.08, [1.17, 2.99], P = 8.22 × 10-6), implicating metabolic and appetite regulation pathways for the alcohol consumption findings. For liver health, HbA1c lowering via GIPR/GLP1R was associated with reduced NAFLD (β = -0.34, [-0.50, -0.18], P = 2.74 × 10-5) and lower ALT levels (β = -0.26, [-0.38, -0.15], P = 8.39 × 10-6), with replication supporting these findings. Consistency across multiple MR methods and colocalization analyses strengthened causal inference. Mediation analysis suggested reductions in hazardous alcohol consumption partially explain the cardioprotective effects of these agonists. Multi-ancestry analyses supported directionally aligned relationships in non-European cohorts. These findings support further clinical exploration of GLP1R, GIPR, and dual agonists in addiction medicine.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Reitz J, Rosoff DB, Perlstein T, et al. Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study. Mol Psychiatry. 2025. PMID: 40931165. doi:10.1038/s41380-025-03199-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。